Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma

Orazio Schillaci, Gerald L Denardo, Sally J. DeNardo, Desiree S. Goldstein, Linda A. Kroger, Robert T O'Donnell, Kathleen R. Lamborn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (Rituxan®, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., South San Francisco, CA) or radiolabeled 90Y-ibritumomab (Zevalin®, Biogen Idec Inc., Cambridge, MA) and 131I-tositumomab (Bexxar®; Glaxo Smith Kline, Research Triangle Park, NC), have proven to be effective therapy for non-Hodgkin's lymphoma (NHL), but also induce immediate and persistent decreases in normal peripheral blood lymphocytes (PBLs). Lym-1, a mAb that selectively targets malignant lymphocytes, also has induced therapeutic responses and prolonged survival in patients with NHL when labeled with iodine-131 ( 131I). We have retrospectively examined its effect on PBLs in 41 NHL patients that had received 131I-Lym-1 therapy. Absolute lymphocyte counts (ALCs) were evaluated before and after the first and last 131I-Lym-1 infusion. Modest decreases in PBLs were observed in most of the patients. Using strict criteria to define recovery, time to recovery was determined for 19 patients, with the remainder censored because of insufficient follow-up (median follow up for censored patients: 22 days). Using Kaplan-Meier estimates, it would be predicted that 31% of patients would recover by 28 days and that median time to recovery would be 44 days after the last 131I-Lym-1 infusion. No predictors were found for time to recovery, considering such factors as the administered Lym-1 or 1311 dose, spleen volume, or radiation doses to the body, marrow, or spleen. The data suggest that the effect of 131I-Lym-1 on ALC is the result of a nonspecific radiation effect, rather than a specific Lym-1 mAb effect. The shorter time required for ALC recovery after 131I-Lym-1 when compared to that reported for anti-CD20 mAbs, whether radiolabeled or otherwise, is probably related to differing mechanisms for lymphocytotoxicity and lesser Lym-1 antigenic density on normal B-lymphocytes.

Original languageEnglish (US)
Pages (from-to)521-530
Number of pages10
JournalCancer Biotherapy and Radiopharmaceuticals
Volume22
Issue number4
DOIs
StatePublished - Aug 2007

Fingerprint

Non-Hodgkin's Lymphoma
Lymphocytes
Antibodies
Lymphocyte Count
Spleen
Monoclonal Antibodies
San Francisco
Radiation Effects
Kaplan-Meier Estimate
Iodine
B-Lymphocytes
Therapeutics
Bone Marrow
Radiation
Survival
Research
Rituximab

Keywords

  • Antibody
  • Lymphocyte
  • Lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. / Schillaci, Orazio; Denardo, Gerald L; DeNardo, Sally J.; Goldstein, Desiree S.; Kroger, Linda A.; O'Donnell, Robert T; Lamborn, Kathleen R.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 22, No. 4, 08.2007, p. 521-530.

Research output: Contribution to journalArticle

Schillaci, Orazio ; Denardo, Gerald L ; DeNardo, Sally J. ; Goldstein, Desiree S. ; Kroger, Linda A. ; O'Donnell, Robert T ; Lamborn, Kathleen R. / Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. In: Cancer Biotherapy and Radiopharmaceuticals. 2007 ; Vol. 22, No. 4. pp. 521-530.
@article{6cf6b6a81fdb46e0b3c1485cdc1f9def,
title = "Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma",
abstract = "Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (Rituxan{\circledR}, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., South San Francisco, CA) or radiolabeled 90Y-ibritumomab (Zevalin{\circledR}, Biogen Idec Inc., Cambridge, MA) and 131I-tositumomab (Bexxar{\circledR}; Glaxo Smith Kline, Research Triangle Park, NC), have proven to be effective therapy for non-Hodgkin's lymphoma (NHL), but also induce immediate and persistent decreases in normal peripheral blood lymphocytes (PBLs). Lym-1, a mAb that selectively targets malignant lymphocytes, also has induced therapeutic responses and prolonged survival in patients with NHL when labeled with iodine-131 ( 131I). We have retrospectively examined its effect on PBLs in 41 NHL patients that had received 131I-Lym-1 therapy. Absolute lymphocyte counts (ALCs) were evaluated before and after the first and last 131I-Lym-1 infusion. Modest decreases in PBLs were observed in most of the patients. Using strict criteria to define recovery, time to recovery was determined for 19 patients, with the remainder censored because of insufficient follow-up (median follow up for censored patients: 22 days). Using Kaplan-Meier estimates, it would be predicted that 31{\%} of patients would recover by 28 days and that median time to recovery would be 44 days after the last 131I-Lym-1 infusion. No predictors were found for time to recovery, considering such factors as the administered Lym-1 or 1311 dose, spleen volume, or radiation doses to the body, marrow, or spleen. The data suggest that the effect of 131I-Lym-1 on ALC is the result of a nonspecific radiation effect, rather than a specific Lym-1 mAb effect. The shorter time required for ALC recovery after 131I-Lym-1 when compared to that reported for anti-CD20 mAbs, whether radiolabeled or otherwise, is probably related to differing mechanisms for lymphocytotoxicity and lesser Lym-1 antigenic density on normal B-lymphocytes.",
keywords = "Antibody, Lymphocyte, Lymphoma, Radioimmunotherapy",
author = "Orazio Schillaci and Denardo, {Gerald L} and DeNardo, {Sally J.} and Goldstein, {Desiree S.} and Kroger, {Linda A.} and O'Donnell, {Robert T} and Lamborn, {Kathleen R.}",
year = "2007",
month = "8",
doi = "10.1089/cbr.2007.374",
language = "English (US)",
volume = "22",
pages = "521--530",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma

AU - Schillaci, Orazio

AU - Denardo, Gerald L

AU - DeNardo, Sally J.

AU - Goldstein, Desiree S.

AU - Kroger, Linda A.

AU - O'Donnell, Robert T

AU - Lamborn, Kathleen R.

PY - 2007/8

Y1 - 2007/8

N2 - Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (Rituxan®, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., South San Francisco, CA) or radiolabeled 90Y-ibritumomab (Zevalin®, Biogen Idec Inc., Cambridge, MA) and 131I-tositumomab (Bexxar®; Glaxo Smith Kline, Research Triangle Park, NC), have proven to be effective therapy for non-Hodgkin's lymphoma (NHL), but also induce immediate and persistent decreases in normal peripheral blood lymphocytes (PBLs). Lym-1, a mAb that selectively targets malignant lymphocytes, also has induced therapeutic responses and prolonged survival in patients with NHL when labeled with iodine-131 ( 131I). We have retrospectively examined its effect on PBLs in 41 NHL patients that had received 131I-Lym-1 therapy. Absolute lymphocyte counts (ALCs) were evaluated before and after the first and last 131I-Lym-1 infusion. Modest decreases in PBLs were observed in most of the patients. Using strict criteria to define recovery, time to recovery was determined for 19 patients, with the remainder censored because of insufficient follow-up (median follow up for censored patients: 22 days). Using Kaplan-Meier estimates, it would be predicted that 31% of patients would recover by 28 days and that median time to recovery would be 44 days after the last 131I-Lym-1 infusion. No predictors were found for time to recovery, considering such factors as the administered Lym-1 or 1311 dose, spleen volume, or radiation doses to the body, marrow, or spleen. The data suggest that the effect of 131I-Lym-1 on ALC is the result of a nonspecific radiation effect, rather than a specific Lym-1 mAb effect. The shorter time required for ALC recovery after 131I-Lym-1 when compared to that reported for anti-CD20 mAbs, whether radiolabeled or otherwise, is probably related to differing mechanisms for lymphocytotoxicity and lesser Lym-1 antigenic density on normal B-lymphocytes.

AB - Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (Rituxan®, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., South San Francisco, CA) or radiolabeled 90Y-ibritumomab (Zevalin®, Biogen Idec Inc., Cambridge, MA) and 131I-tositumomab (Bexxar®; Glaxo Smith Kline, Research Triangle Park, NC), have proven to be effective therapy for non-Hodgkin's lymphoma (NHL), but also induce immediate and persistent decreases in normal peripheral blood lymphocytes (PBLs). Lym-1, a mAb that selectively targets malignant lymphocytes, also has induced therapeutic responses and prolonged survival in patients with NHL when labeled with iodine-131 ( 131I). We have retrospectively examined its effect on PBLs in 41 NHL patients that had received 131I-Lym-1 therapy. Absolute lymphocyte counts (ALCs) were evaluated before and after the first and last 131I-Lym-1 infusion. Modest decreases in PBLs were observed in most of the patients. Using strict criteria to define recovery, time to recovery was determined for 19 patients, with the remainder censored because of insufficient follow-up (median follow up for censored patients: 22 days). Using Kaplan-Meier estimates, it would be predicted that 31% of patients would recover by 28 days and that median time to recovery would be 44 days after the last 131I-Lym-1 infusion. No predictors were found for time to recovery, considering such factors as the administered Lym-1 or 1311 dose, spleen volume, or radiation doses to the body, marrow, or spleen. The data suggest that the effect of 131I-Lym-1 on ALC is the result of a nonspecific radiation effect, rather than a specific Lym-1 mAb effect. The shorter time required for ALC recovery after 131I-Lym-1 when compared to that reported for anti-CD20 mAbs, whether radiolabeled or otherwise, is probably related to differing mechanisms for lymphocytotoxicity and lesser Lym-1 antigenic density on normal B-lymphocytes.

KW - Antibody

KW - Lymphocyte

KW - Lymphoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=34548621763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548621763&partnerID=8YFLogxK

U2 - 10.1089/cbr.2007.374

DO - 10.1089/cbr.2007.374

M3 - Article

C2 - 17803447

AN - SCOPUS:34548621763

VL - 22

SP - 521

EP - 530

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -